Biofrontera (BFRI) Competitors $0.78 -0.03 (-3.42%) Closing price 04:00 PM EasternExtended Trading$0.81 +0.03 (+4.47%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. IXHL, ZYBT, NBRV, ELUT, and INCRShould you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include Incannex Healthcare (IXHL), Zhengye Biotechnology (ZYBT), Nabriva Therapeutics (NBRV), Elutia (ELUT), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. BFRI vs. IXHLBFRI vs. ZYBTBFRI vs. NBRVBFRI vs. ELUTBFRI vs. INCRHow does Biofrontera compare to Incannex Healthcare?Biofrontera (NASDAQ:BFRI) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Which has more risk & volatility, BFRI or IXHL? Biofrontera has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, suggesting that its share price is 622% more volatile than the broader market. Does the media refer more to BFRI or IXHL? In the previous week, Biofrontera had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Biofrontera and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.11 beat Biofrontera's score of -0.32 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Neutral Incannex Healthcare Positive Is BFRI or IXHL more profitable? Incannex Healthcare has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Incannex Healthcare's return on equity of -81.01% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-25.66% -515.34% -53.91% Incannex Healthcare N/A -81.01%-76.11% Do institutionals & insiders hold more shares of BFRI or IXHL? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer BFRI or IXHL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher earnings & valuation, BFRI or IXHL? Biofrontera has higher revenue and earnings than Incannex Healthcare. Biofrontera is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$41.71M0.24-$10.54M-$0.97N/AIncannex Healthcare$90K484.12-$46.88M-$8.41N/A SummaryBiofrontera beats Incannex Healthcare on 9 of the 15 factors compared between the two stocks.How does Biofrontera compare to Zhengye Biotechnology?Biofrontera (NASDAQ:BFRI) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Does the media prefer BFRI or ZYBT? In the previous week, Biofrontera had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Biofrontera and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Biofrontera's score of -0.32 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Neutral Zhengye Biotechnology Neutral Which has more volatility and risk, BFRI or ZYBT? Biofrontera has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market. Is BFRI or ZYBT more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Zhengye Biotechnology's return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-25.66% -515.34% -53.91% Zhengye Biotechnology N/A N/A N/A Which has stronger earnings & valuation, BFRI or ZYBT? Zhengye Biotechnology has lower revenue, but higher earnings than Biofrontera. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$41.71M0.24-$10.54M-$0.97N/AZhengye Biotechnology$16.64M2.47-$9.98MN/AN/A Do institutionals and insiders believe in BFRI or ZYBT? 10.1% of Biofrontera shares are owned by institutional investors. 4.8% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend BFRI or ZYBT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryBiofrontera beats Zhengye Biotechnology on 7 of the 13 factors compared between the two stocks.How does Biofrontera compare to Nabriva Therapeutics?Nabriva Therapeutics (NASDAQ:NBRV) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Does the media prefer NBRV or BFRI? In the previous week, Biofrontera had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Biofrontera and 1 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 beat Biofrontera's score of -0.32 indicating that Nabriva Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nabriva Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, NBRV or BFRI? Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Which has higher valuation and earnings, NBRV or BFRI? Biofrontera has higher revenue and earnings than Nabriva Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ABiofrontera$41.71M0.24-$10.54M-$0.97N/A Is NBRV or BFRI more profitable? Biofrontera has a net margin of -25.66% compared to Nabriva Therapeutics' net margin of -148.11%. Nabriva Therapeutics' return on equity of -365.53% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Biofrontera -25.66%-515.34%-53.91% Do analysts prefer NBRV or BFRI? Given Nabriva Therapeutics' higher probable upside, research analysts clearly believe Nabriva Therapeutics is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in NBRV or BFRI? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 4.8% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBiofrontera beats Nabriva Therapeutics on 10 of the 15 factors compared between the two stocks.How does Biofrontera compare to Elutia?Biofrontera (NASDAQ:BFRI) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk. Which has stronger valuation and earnings, BFRI or ELUT? Elutia has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$41.71M0.24-$10.54M-$0.97N/AElutia$12.29M4.18$53.38M$0.861.40 Do analysts recommend BFRI or ELUT? Elutia has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Elutia 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor BFRI or ELUT? In the previous week, Elutia had 1 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Elutia and 4 mentions for Biofrontera. Biofrontera's average media sentiment score of -0.32 beat Elutia's score of -0.33 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, BFRI or ELUT? Biofrontera has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Elutia has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Do institutionals & insiders have more ownership in BFRI or ELUT? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 4.8% of Biofrontera shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is BFRI or ELUT more profitable? Elutia has a net margin of 312.09% compared to Biofrontera's net margin of -25.66%. Elutia's return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-25.66% -515.34% -53.91% Elutia 312.09%N/A -53.97% SummaryElutia beats Biofrontera on 11 of the 15 factors compared between the two stocks.How does Biofrontera compare to InterCure?Biofrontera (NASDAQ:BFRI) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Which has better earnings & valuation, BFRI or INCR? InterCure has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$41.71M0.24-$10.54M-$0.97N/AInterCure$78.47M0.59-$10.37M$0.0328.22 Does the media refer more to BFRI or INCR? In the previous week, Biofrontera had 4 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Biofrontera and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 beat Biofrontera's score of -0.32 indicating that InterCure is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Neutral InterCure Neutral Which has more volatility and risk, BFRI or INCR? Biofrontera has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, InterCure has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Is BFRI or INCR more profitable? InterCure has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. InterCure's return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-25.66% -515.34% -53.91% InterCure N/A N/A N/A Do institutionals and insiders have more ownership in BFRI or INCR? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend BFRI or INCR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryInterCure beats Biofrontera on 10 of the 15 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition ExportMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.97M$3.36B$6.34B$12.29BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-0.8019.0120.9425.47Price / Sales0.24278.84521.1573.36Price / CashN/A125.3543.1855.00Price / Book1.666.909.987.00Net Income-$10.54M$24.23M$3.55B$335.16M7 Day Performance-21.29%0.59%0.42%-0.29%1 Month Performance-28.51%-0.61%0.00%1.15%1 Year Performance20.60%63.26%34.99%34.79% Biofrontera Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera0.6557 of 5 stars$0.78-3.4%N/A+22.4%$9.97M$41.71MN/A70News CoverageEarnings ReportIXHLIncannex Healthcare0.9345 of 5 stars$3.85-1.3%N/A-48.5%$45.94MN/AN/A3Positive NewsZYBTZhengye BiotechnologyN/A$0.96-5.0%N/A-88.5%$45.46M$116.36MN/A278Gap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59MN/A70ELUTElutia2.8826 of 5 stars$1.05flat$6.00+471.4%-35.2%$44.92M$12.29M1.28180Earnings ReportGap Down Related Companies and Tools Related Companies IXHL Competitors ZYBT Competitors NBRV Competitors ELUT Competitors INCR Competitors ATOS Competitors LITS Competitors HYPD Competitors TAOX Competitors TELO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
